Durvalumab with R-CHOP or lenalidomide in DLBCL
Ulrich Jäger | EHA 2018 | What are the potential causes of aggressive B-cell lymphomas under JAK1/2 inhibition?
Ulrich Jäger on the potential causes of agressive B-cell lymphomas under JAK1/2 inhibition, EHA 2018
A subset of DLBCL cases with 9p24.1 ampliﬁcation reveals molecular and genetic features similar to PMBCL
In a paper published in Blood Cancer Journal, Yucai Wang and colleagues analysed the frequency of 9p24.1 CNA in untreated newly diagnosed DLBCL,...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox every month